Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Concentrated bone marrow aspirate (cBMA) is an autologous cell-based biologic therapy being investigated by the Hospital for Special Surgery (HSS) for the treatment and prevention of post-traumatic osteoarthritis (PTOA) following revision anterior cruciate ligament (ACL) reconstruction. The therapy involves the intraoperative harvest of bone marrow from the patient's iliac crest, which is then processed via centrifugation to create a concentrate rich in autologous bone marrow cells, including mesenchymal stem cells, anti-inflammatory mediators, and immune-modulating proteins. This concentrate is injected into the knee joint to reduce local inflammation and improve clinical outcomes such as pain and joint function. The study is part of the Arthritis Foundation 2023 FastOA Interventional Pilot Studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Concentrated bone marrow aspirate (Hospital for Special Surgery).